Immune signatures of chronic inflammatory human diseases driving cancer

The laboratory of Mathias Heikenwälder aims at understanding the different immune signatures of chronic inflammatory human diseases driving cancer - with the final aim to generate appropriate mouse models used for pre-clinical research and translation into the clinic. A focus of the laboratory is to understand how inflammation (induced by life-style factors or pathogens (e.g. viruses or bacteria)) drives cancer in regenerative organs (such as the liver or the gastrointestinal tract).

A particular research focus of the Mathias Heikenwälder laboratory is the elucidation of the molecular and cellular mechanisms causing fatty liver disease, subsequent inflammation,  tissue damage (called non-alcoholic steatohepatitis (NASH)) and resulting liver cancer. Life-style related factors have contributed to the fact that today liver cancer is the 4th most common cause for cancer-related death and the fastest rising cancer in the world.

Mainly caused by a sedentary life style and hypercaloric nutrition, NASH is one of the leading causes of chronic liver disease with the potential of evolving towards end-stage liver disease and hepatocellular carcinoma (HCC), even in the absence of cirrhosis. Every third American and European citizen has a fatty liver. Apart from becoming an increasingly prevalent indication for liver transplantation in cirrhotic and HCC patients, its burden on the healthcare system is also exerted by the increased number of non-cirrhotic NASH patients. Currently, there are no efficient therapies available that would either prevent NASH, revert fibrosis or block NASH to HCC transition.

The Heikenwälder laboratory focuses on comparative studies of human and animal model tissues, recapitulating human disease on a histo-pathological and pathophysiological level, engaging in classical molecular biology techniques complemented with sophisticated ways to receive as much information from tissue samples through histology (e.g. light microscopy/ immune fluorescence/ FISH/ in situ hybridization), other in vivo imaging techniques (e.g. MRI) as well as through FACS analyses for tissue homogenates. At the same time the systemic functional effects of pathologies and the interplay between several affected non-lymphoid organs and the immune system is investigated. Testing several therapeutic compounds in a single but also combinatorial fashion is executed in the Heikenwälder laboratory employing established and stratified pre-clinical mouse models.

In the past the Heikenwälder laboratory has elucidated how the adaptive and innate immune system drives NASH and affects therapy response (e.g. in the context of systemic liver cancer therapy) - which has led to the generation of drugs that are currently tested for clinical use. Mathias Heikenwälder is an elected member of the Leopoldina, most highly cited researcher world-wide from 2018-2022 (“Cross Topic” Web of Science) and has received several prestigious grants (ERC-Stg, ERC-CoG; ERC-POC) and awards (Prof. Max Cloetta award, Götz prize, Walther and Christine Richtzenhain award, Prof. Hans Peter Hofschneider award). In 2022 he has received the German Cancer award.  

Prof. Mathias Heikenwälder is a trained molecular biologist, with expertise in immunology and a strong link to translational research evoked by 10 years of work and expertise in a Pathology Institution (Clinical Pathology, University Hospital Zurich). Since October 2015 he is Department head at the German Cancer Research Center (DKFZ) in Heidelberg focusing on the link between chronic inflammation and cancer. Since October 2022 he is director of the M3 Research Center, University Tübingen. Prof. Heikenwälder publishes his work in high-ranking journals and has established himself as an international leader in the field of liver cancer. Mathias Heikenwälder is the third most frequently cited German-speaking researcher in the field of cell biology in the last years and was one of the Highly Cited Researchers (Cross Fields) (Web of Science Group) in 2019, 2020, 2021 and 2022. Not only have his publications been widely cited by the research community, but they have also shifted fatty liver and liver cancer research in new directions - relevant to the day-to-day management of patients with fatty liver or liver cancer.

Interview
Immune signatures of chronic inflammatory human diseases driving cancer - Interview with Prof. Dr. Mathias Heikenwälder

Prof. Mathias Heikenwälder speaks about the research focus, the technologies executed as well as the overall translational work and overall goals of this research laboratory.

Beim Abspielen des Videos werden Daten an YouTube übertragen. Weitere Hinweise finden Sie in unserer Datenschutzerklärung.

  • Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
  • Cluster of Excellence “Image-guided and functionally instructed tumor therapies" (iFIT), University of Tübingen, Germany
  • Cluster of Excellence "Controlling Microbes to Fight Infections" (CMFI), University of Tübingen, Germany

Open positions

The research focus of our laboratory is to investigate the role of chronic inflammation induced tissue damage and cancer caused by different environmental triggers:

  • Chronic infections with viruses, bacteria and their role in affecting the tumor directly (intratumoral) or the tumor microenvironment
  • Unhealthy life style (hyper caloric diet in combination with a sedentary life style; chronic smoking or alcohol abuse) and interconnected aberrant metabolism or chronic inflammation 
  • Generation of therapeutic concepts (e.g. combinatorial therapies; identification of novel targets) and life-style interventions (e.g. intermittent fasting)

 

NASH
non-alcoholic steatohepatitis
inflammation
driving cancer in regenerative organs
HCC
hepatocellular carcinoma

Selected publications

  • Single-cell profiling of intrahepatic immune cells reveals an expansion of tissue-resident cytotoxic CD4+ T lymphocyte subset associated with pathogenesis of alcoholic-associated liver diseases

    Gao C, Wang S, Xie X, Ramadori P, Li X, Liu X, Ding X, Liang J, Xu B, Feng Y, Tan X, Wang H, Zhang Y, Zhang H, Zhang T, Mi P, Li S, Zhang C, Yuan D, Heikenwalder M, Zhang P. Single-cell Profiling of Intrahepatic Immune Cells Reveals an Expansion of Tissue-resident Cytotoxic CD4+ T Lymphocyte Subset Associated With Pathogenesis of Alcoholic-associated Liver Diseases. Cell Mol Gastroenterol Hepatol. 2025;19(2):101411. doi: 10.1016/j.jcmgh.2024.101411. Epub 2024 Sep 28. PMID: 39349248; PMCID: PMC11719870. https://doi.org/10.1016/j.jcmgh.2024.101411
  • TNF compromises intestinal bile-acid tolerance dictating colitis progression and limited infliximab response

    Zheng M, Zhai Y, Yu Y, Shen J, Chu S, Focaccia E, Tian W, Wang S, Liu X, Yuan X, Wang Y, Li L, Feng B, Li Z, Guo X, Qiu J, Zhang C, Hou J, Sun Y, Yang X, Zuo X, Heikenwalder M, Li Y, Yuan D, Li S. TNF compromises intestinal bile-acid tolerance dictating colitis progression and limited infliximab response. Cell Metab. 2024 Sep 3;36(9):2086-2103.e9. doi: 10.1016/j.cmet.2024.06.008. Epub 2024 Jul 5. PMID: 38971153. https://doi.org/10.1016/j.cmet.2024.06.008
  • HBV-related HCC development in mice is STAT3 dependent and indicates an oncogenic effect of HBx

    Ringelhan M, Schuehle S, van de Klundert M, Kotsiliti E, Plissonnier ML, Faure-Dupuy S, Riedl T, Lange S, Wisskirchen K, Thiele F, Cheng CC, Yuan D, Leone V, Schmidt R, Hünergard J, Geisler F, Unger K, Algül H, Schmid RM, Rad R, Wedemeyer H, Levrero M, Protzer U, Heikenwalder M. HBV-related HCC development in mice is STAT3 dependent and indicates an oncogenic effect of HBx. JHEP Rep. 2024 Jun 6;6(10):101128. doi: 10.1016/j.jhepr.2024.101128. PMID: 39290403; PMCID: PMC11406364. https://doi.org/10.1016/j.jhepr.2024.101128
  • Ribosomal S6 kinase 1 regulates inflammaging via the senescence secretome

    Gallage S, Irvine EE, Barragan Avila JE, Reen V, Pedroni SMA, Duran I, Ranvir V, Khadayate S, Pombo J, Brookes S, Heide D, Dharmalingham G, Choudhury AI, Singh I, Herranz N, Vernia S, Heikenwalder M, Gil J, Withers DJ. Ribosomal S6 kinase 1 regulates inflammaging via the senescence secretome. Nat Aging. 2024 Nov;4(11):1544-1561. doi: 10.1038/s43587-024-00695-z. Epub 2024 Aug 29. PMID: 39210150; PMCID: PMC11564105. https://doi.org/10.1038/s43587-024-00695-z
  • A 5:2 intermittent fasting regimen ameliorates NASH and fibrosis and blunts HCC development via hepatic PPARα and PCK1

    Gallage S, Ali A, Barragan Avila JE, Seymen N, Ramadori P, Joerke V, Zizmare L, Aicher D, Gopalsamy IK, Fong W, Kosla J, Focaccia E, Li X, Yousuf S, Sijmonsma T, Rahbari M, Kommoss KS, Billeter A, Prokosch S, Rothermel U, Mueller F, Hetzer J, Heide D, Schinkel B, Machauer T, Pichler B, Malek NP, Longerich T, Roth S, Rose AJ, Schwenck J, Trautwein C, Karimi MM, Heikenwalder M. A 5:2 intermittent fasting regimen ameliorates NASH and fibrosis and blunts HCC development via hepatic PPARα and PCK1. Cell Metab. 2024 Jun 4;36(6):1371-1393.e7. doi: 10.1016/j.cmet.2024.04.015. Epub 2024 May 7. PMID: 38718791. https://doi.org/10.1016/j.cmet.2024.04.015
  • Intestinal B-cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling

    Kotsiliti E, Leone V, Schuehle S, Govaere O, Li H, Wolf MJ, Horvatic H, Bierwirth S, Hundertmark J, Inverso D, Zizmare L, Sarusi-Portuguez A, Gupta R, O'Connor T, Giannou AD, Shiri AM, Schlesinger Y, Beccaria MG, Rennert C, Pfister D, Öllinger R, Gadjalova I, Ramadori P, Rahbari M, Rahbari N, Healy ME, Fernández-Vaquero M, Yahoo N, Janzen J, Singh I, Fan C, Liu X, Rau M, Feuchtenberger M, Schwaneck E, Wallace SJ, Cockell S, Wilson-Kanamori J, Ramachandran P, Kho C, Kendall TJ, Leblond AL, Keppler SJ, Bielecki P, Steiger K, Hofmann M, Rippe K, Zitzelsberger H, Weber A, Malek N, Luedde T, Vucur M, Augustin HG, Flavell R, Parnas O, Rad R, Pabst O, Henderson NC, Huber S, Macpherson A, Knolle P, Claassen M, Geier A, Trautwein C, Unger K, Elinav E, Waisman A, Abdullah Z, Haller D, Tacke F, Anstee QM, Heikenwalder M. Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling. J Hepatol. 2023 Aug;79(2):296-313. doi: 10.1016/j.jhep.2023.04.037. Epub 2023 May 22. PMID: 37224925; PMCID: PMC10360918. https://doi.org/10.1016/j.jhep.2023.04.037
  • XCR1+ type 1 conventional dendritic cells drive liver pathology in Non-Alcoholic Steatohepatitis

    Deczkowska A, David E, Ramadori P, Pfister D, Safran M, Li B, Giladi A, Jaitin DA, Barboy O, Cohen M, Yofe I, Gur C, Shlomi-Loubaton S, Henri S, Suhail Y, Qiu M, Kam S, Hermon H, Lahat E, Ben Yakov G, Cohen-Ezra O, Davidov Y, Likhter M, Goitein D, Roth S, Weber A, Malissen B, Weiner A, Ben-Ari Z, Heikenwälder M, Elinav E, Amit I. XCR1+ type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis. Nat Med. 2021 Jun;27(6):1043-1054. doi: 10.1038/s41591-021-01344-3. Epub 2021 May 20. Erratum in: Nat Med. 2022 Jan;28(1):214. doi: 10.1038/s41591-021-01668-0. PMID: 34017133. https://doi.org/10.1038/s41591-021-01344-3
  • NASH limits anti-tumour surveillance in immunotherapy-treated HCC

    Pfister D, Núñez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, Gupta R, Qiu M, Deczkowska A, Weiner A, Müller F, Sinha A, Friebel E, Engleitner T, Lenggenhager D, Moncsek A, Heide D, Stirm K, Kosla J, Kotsiliti E, Leone V, Dudek M, Yousuf S, Inverso D, Singh I, Teijeiro A, Castet F, Montironi C, Haber PK, Tiniakos D, Bedossa P, Cockell S, Younes R, Vacca M, Marra F, Schattenberg JM, Allison M, Bugianesi E, Ratziu V, Pressiani T, D'Alessio A, Personeni N, Rimassa L, Daly AK, Scheiner B, Pomej K, Kirstein MM, Vogel A, Peck-Radosavljevic M, Hucke F, Finkelmeier F, Waidmann O, Trojan J, Schulze K, Wege H, Koch S, Weinmann A, Bueter M, Rössler F, Siebenhüner A, De Dosso S, Mallm JP, Umansky V, Jugold M, Luedde T, Schietinger A, Schirmacher P, Emu B, Augustin HG, Billeter A, Müller-Stich B, Kikuchi H, Duda DG, Kütting F, Waldschmidt DT, Ebert MP, Rahbari N, Mei HE, Schulz AR, Ringelhan M, Malek N, Spahn S, Bitzer M, Ruiz de Galarreta M, Lujambio A, Dufour JF, Marron TU, Kaseb A, Kudo M, Huang YH, Djouder N, Wolter K, Zender L, Marche PN, Decaens T, Pinato DJ, Rad R, Mertens JC, Weber A, Unger K, Meissner F, Roth S, Jilkova ZM, Claassen M, Anstee QM, Amit I, Knolle P, Becher B, Llovet JM, Heikenwalder M. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021 Apr;592(7854):450-456. doi: 10.1038/s41586-021-03362-0. Epub 2021 Mar 24. PMID: 33762733; PMCID: PMC8046670. https://doi.org/10.1038/s41586-021-03362-0
  • Inhibition of LTβR signalling activates WNT-induced regeneration in lung

    Conlon TM, John-Schuster G, Heide D, Pfister D, Lehmann M, Hu Y, Ertüz Z, Lopez MA, Ansari M, Strunz M, Mayr C, Angelidis I, Ciminieri C, Costa R, Kohlhepp MS, Guillot A, Günes G, Jeridi A, Funk MC, Beroshvili G, Prokosch S, Hetzer J, Verleden SE, Alsafadi H, Lindner M, Burgstaller G, Becker L, Irmler M, Dudek M, Janzen J, Goffin E, Gosens R, Knolle P, Pirotte B, Stoeger T, Beckers J, Wagner D, Singh I, Theis FJ, de Angelis MH, O'Connor T, Tacke F, Boutros M, Dejardin E, Eickelberg O, Schiller HB, Königshoff M, Heikenwalder M, Yildirim AÖ. Inhibition of LTβR signalling activates WNT-induced regeneration in lung. Nature. 2020 Dec;588(7836):151-156. doi: 10.1038/s41586-020-2882-8. Epub 2020 Nov 4. Erratum in: Nature. 2021 Jan;589(7842):E6. doi: 10.1038/s41586-020-03087-6. PMID: 33149305; PMCID: PMC7718297. https://doi.org/10.1038/s41586-020-2882-8
  • Age-Related Gliosis Promotes Central Nervous System Lymphoma through CCL19-Mediated Tumor Cell Retention

    O'Connor T, Zhou X, Kosla J, Adili A, Garcia Beccaria M, Kotsiliti E, Pfister D, Johlke AL, Sinha A, Sankowski R, Schick M, Lewis R, Dokalis N, Seubert B, Höchst B, Inverso D, Heide D, Zhang W, Weihrich P, Manske K, Wohlleber D, Anton M, Hoellein A, Seleznik G, Bremer J, Bleul S, Augustin HG, Scherer F, Koedel U, Weber A, Protzer U, Förster R, Wirth T, Aguzzi A, Meissner F, Prinz M, Baumann B, Höpken UE, Knolle PA, von Baumgarten L, Keller U, Heikenwalder M. Age-Related Gliosis Promotes Central Nervous System Lymphoma through CCL19-Mediated Tumor Cell Retention. Cancer Cell. 2019 Sep 16;36(3):250-267.e9. doi: 10.1016/j.ccell.2019.08.001. Erratum in: Cancer Cell. 2025 Jul 14;43(7):1377-1384. doi: 10.1016/j.ccell.2025.06.009. PMID: 31526758. https://doi.org/10.1016/j.ccell.2019.08.001
  • Platelet GPIba is a mediator and potential interventional target for NASH and subsequent liver cancer

    Malehmir M, Pfister D, Gallage S, Szydlowska M, Inverso D, Kotsiliti E, Leone V, Peiseler M, Surewaard BGJ, Rath D, Ali A, Wolf MJ, Drescher H, Healy ME, Dauch D, Kroy D, Krenkel O, Kohlhepp M, Engleitner T, Olkus A, Sijmonsma T, Volz J, Deppermann C, Stegner D, Helbling P, Nombela-Arrieta C, Rafiei A, Hinterleitner M, Rall M, Baku F, Borst O, Wilson CL, Leslie J, O'Connor T, Weston CJ, Chauhan A, Adams DH, Sheriff L, Teijeiro A, Prinz M, Bogeska R, Anstee N, Bongers MN, Notohamiprodjo M, Geisler T, Withers DJ, Ware J, Mann DA, Augustin HG, Vegiopoulos A, Milsom MD, Rose AJ, Lalor PF, Llovet JM, Pinyol R, Tacke F, Rad R, Matter M, Djouder N, Kubes P, Knolle PA, Unger K, Zender L, Nieswandt B, Gawaz M, Weber A, Heikenwalder M. Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer. Nat Med. 2019 Apr;25(4):641-655. doi: 10.1038/s41591-019-0379-5. Epub 2019 Apr 1. Erratum in: Nat Med. 2022 Mar;28(3):600. doi: 10.1038/s41591-022-01693-7. PMID: 30936549; PMCID: PMC12452109. https://doi.org/10.1038/s41591-019-0379-5
  • Single cell polarity in liquid phase facilitates tumour metastasis

    Lorentzen A, Becker PF, Kosla J, Saini M, Weidele K, Ronchi P, Klein C, Wolf MJ, Geist F, Seubert B, Ringelhan M, Mihic-Probst D, Esser K, Roblek M, Kuehne F, Bianco G, O'Connor T, Müller Q, Schuck K, Lange S, Hartmann D, Spaich S, Groß O, Utikal J, Haferkamp S, Sprick MR, Damle-Vartak A, Hapfelmeier A, Hüser N, Protzer U, Trumpp A, Saur D, Vartak N, Klein CA, Polzer B, Borsig L, Heikenwalder M. Single cell polarity in liquid phase facilitates tumour metastasis. Nat Commun. 2018 Feb 28;9(1):887. doi: 10.1038/s41467-018-03139-6. PMID: 29491397; PMCID: PMC5830403. https://doi.org/10.1038/s41467-018-03139-6
  • Kupffer-cell derived TNF triggers cholangiocellular tumorigenesis through JNK due to chronic mitochondrial dysfunction and ROS

    Yuan D, Huang S, Berger E, Liu L, Gross N, Heinzmann F, Ringelhan M, Connor TO, Stadler M, Meister M, Weber J, Öllinger R, Simonavicius N, Reisinger F, Hartmann D, Meyer R, Reich M, Seehawer M, Leone V, Höchst B, Wohlleber D, Jörs S, Prinz M, Spalding D, Protzer U, Luedde T, Terracciano L, Matter M, Longerich T, Knolle P, Ried T, Keitel V, Geisler F, Unger K, Cinnamon E, Pikarsky E, Hüser N, Davis RJ, Tschaharganeh DF, Rad R, Weber A, Zender L, Haller D, Heikenwalder M. Kupffer Cell-Derived Tnf Triggers Cholangiocellular Tumorigenesis through JNK due to Chronic Mitochondrial Dysfunction and ROS. Cancer Cell. 2017 Jun 12;31(6):771-789.e6. doi: 10.1016/j.ccell.2017.05.006. Erratum in: Cancer Cell. 2026 Jan 31:S1535-6108(26)00052-8. doi: 10.1016/j.ccell.2026.01.013. PMID: 28609656; PMCID: PMC7909318. https://doi.org/10.1016/j.ccell.2017.05.006
  • Dual Role of Caspase-8 in Triggering and Sensing Proliferation-Associated DNA Damage, a Key Determinant of Liver Cancer Development

    Boege Y, Malehmir M, Healy ME, Bettermann K, Lorentzen A, Vucur M, Ahuja AK, Böhm F, Mertens JC, Shimizu Y, Frick L, Remouchamps C, Mutreja K, Kähne T, Sundaravinayagam D, Wolf MJ, Rehrauer H, Koppe C, Speicher T, Padrissa-Altés S, Maire R, Schattenberg JM, Jeong JS, Liu L, Zwirner S, Boger R, Hüser N, Davis RJ, Müllhaupt B, Moch H, Schulze-Bergkamen H, Clavien PA, Werner S, Borsig L, Luther SA, Jost PJ, Weinlich R, Unger K, Behrens A, Hillert L, Dillon C, Di Virgilio M, Wallach D, Dejardin E, Zender L, Naumann M, Walczak H, Green DR, Lopes M, Lavrik I, Luedde T, Heikenwalder M, Weber A. A Dual Role of Caspase-8 in Triggering and Sensing Proliferation-Associated DNA Damage, a Key Determinant of Liver Cancer Development. Cancer Cell. 2017 Sep 11;32(3):342-359.e10. doi: 10.1016/j.ccell.2017.08.010. PMID: 28898696; PMCID: PMC5598544. https://doi.org/10.1016/j.ccell.2017.08.010
  • Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma

    Finkin S, Yuan D, Stein I, Taniguchi K, Weber A, Unger K, Browning JL, Goossens N, Nakagawa S, Gunasekaran G, Schwartz ME, Kobayashi M, Kumada H, Berger M, Pappo O, Rajewsky K, Hoshida Y, Karin M, Heikenwalder M, Ben-Neriah Y, Pikarsky E. Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. Nat Immunol. 2015 Dec;16(12):1235-44. doi: 10.1038/ni.3290. Epub 2015 Oct 26. PMID: 26502405; PMCID: PMC4653079. https://doi.org/10.1038/ni.3290
  • Metabolic Activation of Intrahepatic CD8+ T Cells and NKT Cells Causes Nonalcoholic Steatohepatitis and Liver Cancer via Cross-Talk with Hepatocytes

    Wolf MJ, Adili A, Piotrowitz K, Abdullah Z, Boege Y, Stemmer K, Ringelhan M, Simonavicius N, Egger M, Wohlleber D, Lorentzen A, Einer C, Schulz S, Clavel T, Protzer U, Thiele C, Zischka H, Moch H, Tschöp M, Tumanov AV, Haller D, Unger K, Karin M, Kopf M, Knolle P, Weber A, Heikenwalder M. Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. Cancer Cell. 2014 Oct 13;26(4):549-64. doi: 10.1016/j.ccell.2014.09.003. PMID: 25314080. https://doi.org/10.1016/j.ccell.2014.09.003
  • Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA

    Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, Sprinzl MF, Koppensteiner H, Makowska Z, Volz T, Remouchamps C, Chou WM, Thasler WE, Hüser N, Durantel D, Liang TJ, Münk C, Heim MH, Browning JL, Dejardin E, Dandri M, Schindler M, Heikenwalder M, Protzer U. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science. 2014 Mar 14;343(6176):1221-8. doi: 10.1126/science.1243462. Epub 2014 Feb 20. PMID: 24557838; PMCID: PMC6309542. https://doi.org/10.1126/science.1243462
  • Intrahepatic myeloid-cell aggregates enable local proliferation of CD8+ T cells and successful immunotherapy against chronic viral liver infection

    Huang LR, Wohlleber D, Reisinger F, Jenne CN, Cheng RL, Abdullah Z, Schildberg FA, Odenthal M, Dienes HP, van Rooijen N, Schmitt E, Garbi N, Croft M, Kurts C, Kubes P, Protzer U, Heikenwalder M, Knolle PA. Intrahepatic myeloid-cell aggregates enable local proliferation of CD8(+) T cells and successful immunotherapy against chronic viral liver infection. Nat Immunol. 2013 Jun;14(6):574-83. doi: 10.1038/ni.2573. Epub 2013 Apr 14. PMID: 23584070. https://doi.org/10.1038/ni.2573
  • Endothelial CCR2 signaling induced by colon carcinoma cells enables extravasation via the JAK2-Stat5 and p38MAPK pathway

    Wolf MJ, Hoos A, Bauer J, Boettcher S, Knust M, Weber A, Simonavicius N, Schneider C, Lang M, Stürzl M, Croner RS, Konrad A, Manz MG, Moch H, Aguzzi A, van Loo G, Pasparakis M, Prinz M, Borsig L, Heikenwalder M. Endothelial CCR2 signaling induced by colon carcinoma cells enables extravasation via the JAK2-Stat5 and p38MAPK pathway. Cancer Cell. 2012 Jul 10;22(1):91-105. doi: 10.1016/j.ccr.2012.05.023. Erratum in: Cancer Cell. 2025 May 12;43(5):988-992. doi: 10.1016/j.ccell.2025.04.012. PMID: 22789541. https://doi.org/10.1016/j.ccr.2012.05.023
  • Lymphotoxin β receptor signaling promotes development of autoimmune pancreatitis

    Seleznik GM, Reding T, Romrig F, Saito Y, Mildner A, Segerer S, Sun LK, Regenass S, Lech M, Anders HJ, McHugh D, Kumagi T, Hiasa Y, Lackner C, Haybaeck J, Angst E, Perren A, Balmer ML, Slack E, MacPherson A, Manz MG, Weber A, Browning JL, Arkan MC, Rülicke T, Aguzzi A, Prinz M, Graf R, Heikenwalder M. Lymphotoxin β receptor signaling promotes development of autoimmune pancreatitis. Gastroenterology. 2012 Nov;143(5):1361-1374. doi: 10.1053/j.gastro.2012.07.112. Epub 2012 Aug 2. PMID: 22863765. https://doi.org/10.1053/j.gastro.2012.07.112
  • A lymphotoxin-driven pathway to hepatocellular carcinoma

    Haybaeck J, Zeller N, Wolf MJ, Weber A, Wagner U, Kurrer MO, Bremer J, Iezzi G, Graf R, Clavien PA, Thimme R, Blum H, Nedospasov SA, Zatloukal K, Ramzan M, Ciesek S, Pietschmann T, Marche PN, Karin M, Kopf M, Browning JL, Aguzzi A, Heikenwalder M. A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell. 2009 Oct 6;16(4):295-308. doi: 10.1016/j.ccr.2009.08.021. Erratum in: Cancer Cell. 2009 Nov 6;16(5):447. Erratum in: Cancer Cell. 2025 Oct 13;43(10):1968-1972. doi: 10.1016/j.ccell.2025.08.005. PMID: 19800575; PMCID: PMC4422166. https://doi.org/10.1016/j.ccr.2009.08.021

Reviews

  • Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation

    Yahoo N, Dudek M, Knolle P, Heikenwälder M. Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation. J Hepatol. 2023 Aug;79(2):538-551. doi: 10.1016/j.jhep.2023.02.033. Epub 2023 Mar 7. PMID: 36893854. https://doi.org/10.1016/j.jhep.2023.02.033
  • A researcher's guide to preclinical mouse NASH models

    Gallage S, Avila JEB, Ramadori P, Focaccia E, Rahbari M, Ali A, Malek NP, Anstee QM, Heikenwalder M. A researcher's guide to preclinical mouse NASH models. Nat Metab. 2022 Dec;4(12):1632-1649. doi: 10.1038/s42255-022-00700-y. Epub 2022 Dec 20. PMID: 36539621. https://doi.org/10.1038/s42255-022-00700-y
  • The immunological and metabolic landscape in primary and metastatic liver cancer

    Li X, Ramadori P, Pfister D, Seehawer M, Zender L, Heikenwalder M. The immunological and metabolic landscape in primary and metastatic liver cancer. Nat Rev Cancer. 2021 Sep;21(9):541-557. doi: 10.1038/s41568-021-00383-9. Epub 2021 Jul 29. PMID: 34326518. https://doi.org/10.1038/s41568-021-00383-9
  • From NASH to HCC: current concepts and future challenges

    Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019 Jul;16(7):411-428. doi: 10.1038/s41575-019-0145-7. PMID: 31028350. https://doi.org/10.1038/s41575-019-0145-7
  • The immunology of hepatocellular carcinoma

    Ringelhan M, Pfister D, O'Connor T, Pikarsky E, Heikenwalder M. The immunology of hepatocellular carcinoma. Nat Immunol. 2018 Mar;19(3):222-232. doi: 10.1038/s41590-018-0044-z. Epub 2018 Jan 29. PMID: 29379119. https://doi.org/10.1038/s41590-018-0044-z
  • Immune receptor for pathogenic α-synuclein

    Jucker M, Heikenwalder M. Immune receptor for pathogenic α-synuclein. Science. 2016 Sep 30;353(6307):1498-1499. doi: 10.1126/science.aai9377. PMID: 27708090. https://doi.org/10.1126/science.aai9377